A distressed, cash-backed in vivo gene-editing option: if ARCUS can erase HBV’s cccDNA, DTIL could re-rate from negative enterprise value to a multi-billion-dollar cure story.
Overview
As of late 2025, Precision BioSciences (DTIL) sits at an inflection point: it is repositioning from a platform-centric gene-editing company into a concentrated, clinical-stage in vivo developer focused on high-value diseases with major unmet need—most notably chronic hepatitis B (HBV) and, next, Duchenne muscular dystrophy (DMD). The company’s thesis rests on ARCUS®, a compact homing-endonuclease editor differentiated from CRISPR by its smaller payload (easier vector packaging), sticky-end cut profile (potentially more precise repair outcomes), and unique ability to reach mitochondria (creating future mtDNA-editing optionality). The lead program, PBGENE‑HBV, targets the viral reservoir (cccDNA) and integrated HBV DNA—aiming for a functional cure rather than ongoing suppression. 2025 Phase 1 ELIMINATE‑B updates provided early human proof-of-concept: dose-dependent HBsAg reductions with a favorable initial safety profile. Financially, DTIL improved survivability via a November 2025 equity/warrant raise (~$75M gross), extending runway into 2H27 but adding meaningful dilution. The stock’s valuation remains distressed—near/below cash and implying a negative enterprise value—creating a highly asymmetric setup where strong 2026–2027 clinical readouts could force a major re-rating, while failure would likely revert the equity toward residual cash and IP value.